Additionally, anti-PD-1/PD-L1 is a more potent type of hypothyroidism-inducing ICI treatment than anti-CTLA4 and a less potent treatment than the combined type (de Filette et al., 2019). The gene discussed is CTLA4; the disease is hypothyroidism.